Pharmaceutical company CoSci Med-Tech led the round, which will help JDP Therapeutics advance a treatment for allergic reactions in hospitals through phase 3 trials.
US-based small molecule therapeutic developer JDP Therapeutics has raised up to $17m in a series A round led by China-headquartered pharmaceutical company CoSci Med-Tech Co.
JDP is developing treatments for serious diseases for use in hospitals and clinics, experimenting with unique dosage forms, formulations or new indications for already proven chemical entities, which it claims reduces risk and shortens the drug development process.
The funding will be used to advance its lead drug candidate, JDP-205, through phase 3 trials and…
